U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07366866) titled 'A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.' on Jan. 07.
Brief Summary: This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Study Start Date: April 28, 2026
Study Type: INTERVENTIONAL
Condition:
Autoimmune Disease
Intervention:
DRUG: GenSci136
Administered SC.
DRUG: Placebo
Administered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health D...